← Leaderboards
Rebecca A Finkel
Childrens Hospital Of Philadelphia
$22,893
Attributed
$22,893
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$22,893 · 3
By mechanism
M01$22,893 · 3
Top collaborators
No co-investigators on record.
Most similar at Childrens Hospital Of Philadelphia
Same institution · by research overlap
- Paige Kaplan$34,549
- Jeffrey C Merrill$70,151
- Athena F Zuppa$6,631,501
- Kevin Edward Meyers$412,566
- Nataliya Zelikovsky$12,682
Others in their field
Top investigators on “Alpha Galactosidase”
- Cheryl Louise Stucky · Medical College Of Wisconsin$4,767,055
- Yu-Teh Li · Tulane University Of Louisiana$3,113,466
- Luc Teyton · Scripps Research Institute, The$2,916,161
- Ervin H Epstein · University Of California San Francisco$2,732,941
- Nancy M. Dahms · Medical College Of Wisconsin$2,662,492
- James Alan Shayman · University Of Michigan At Ann Arbor$2,450,889
Research focus
Alpha GalactosidaseBlood ChemistryClinical ResearchClinical TrialsCreatinineDrug Administration Rate /DurationDrug Screening /EvaluationElectrocardiographyEnzyme TherapyFabry'S DiseaseHuman SubjectHuman Therapy EvaluationInjection /InfusionIsozymesKidney FunctionMetabolism Disorder ChemotherapyPatient Oriented ResearchRecombinant Proteins
Grant awards (4)
SAFETY AND EFFICACY OF FABRAZYME IN PATIENTS WITH FABRY DISEASE$12,041
M01 · FY2005 · RR
DEFINING OUTCOME PARAMETERS FOR CLINICAL TRIALS IN SPINAL MUSCULAR ATROPHY$6,451
M01 · FY2005 · RR
SMN LEVELS IN PERIPHERAL BLOOD SAMPLES OF SMA PATIENTS AND THE EFFECTS OF PHARM$3,010
M01 · FY2005 · RR
Safety and efficacy of Fabrazyme in patients with Fabry disease$1,391
M01 · FY2004 · RR